CJRTP

Chinese Journal of Rehabilitation Theory and Practice >

2017 , Vol. 23 >Issue 2: 173 - 178

DOI: https://doi.org/10.3969/j.issn.1006-9771.2017.02.011

Orginal Article

Treatments and Rehabilitation for Progressive Supranuclear Palsy (review)

  • LIN Wei ,
  • CHEN Ning-yuan
Expand
  • 1. Department of Neurological Rehabilitation, Guangxi Jiangbin Hospital, Nanning, Guangxi 530021, China;
    2. Buck Institute for Research on Aging, Novato, California 94945, USA;
    3. Department of Pathophysiology, Guangxi Medical University, Nanning, Guangxi 530021, China

Received date: 2016-10-13

  Revised date: 2016-11-17

  Online published: 2017-03-06

Fold

Abstract

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease. The etiology and pathogenesis are still unclear. Nowadays there is a lack of an effective molecular marker which can effectively assist the early diagnosis and prognosis of this disease. This article reviewed the pathological anatomy, diagnostic criteria, subtypes and clinical manifestations, imaging studies, scales evaluation, treatment and rehabilitation, complications and risk factors of PSP. Patients with PSP should be managed by a multidisciplinary team. The management of PSP should include the rehabilitation of disorder and palliative treatment, as well as support and education, to improve the quality of life for patients and their caregivers.

Key words： progressive supranuclear palsy; treatment; rehabilitation; review

Cite this article

LIN Wei , CHEN Ning-yuan . Treatments and Rehabilitation for Progressive Supranuclear Palsy (review)[J]. Chinese Journal of Rehabilitation Theory and Practice, 2017 , 23(2) : 173 -178 . DOI: 10.3969/j.issn.1006-9771.2017.02.011

References

[1] Ling H. Clinical approach to progressive supranuclear palsy [J]. J Mov Disord, 2016, 9(1): 3-13.
[2] Kaat DL, Chiu WZ, Boon AJ, et al. Recent advances in progressive supranuclear palsy: a review [J]. Curr Alzheimer Res, 2011, 8(3): 295-302.
[3] Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop [J]. Neurology, 1996, 47(1): 1-9.
[4] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国进行性核上性麻痹临床诊断标准[J]. 中华神经科杂志, 2016, 49(4): 272-276.
[5] Nath U, Thomson R, Wood R, et al. Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) [J]. J Neurol Neurosurg Psychiatry, 2005, 76(4): 498-502.
[6] Ling H, Massey LA, Lees AJ, et al. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease [J]. Brain, 2012, 135(Pt 4): 1141-1153.
[7] Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases [J]. Mov Disord, 2014, 29(14): 1758-1766.
[8] Facheris MF, Maniak S, Scaravilli F, et al. Pure akinesia as initial presentation of PSP: a clinicopathological study [J]. Parkinsonism Relat Disord, 2008, 14(6): 517-519.
[9] Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration [J]. Neurology, 2013, 80(5): 496-503.
[10] Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy [J]. Curr Opin Neurol, 2008, 21(6): 688-692.
[11] Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia [J]. Neurocase, 2012, 18(6): 478-488.
[12] Kanazawa M, Tada M, Onodera O, et al. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia [J]. Parkinsonism Relat Disord, 2013, 19(12): 1149-1151.
[13] Liscic RM, Srulijes K, Gröger A, et al. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools [J]. Acta Neurol Scand, 2013, 127(5): 362-370.
[14] Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy [J]. Radiology, 2008, 246(1): 214-221.
[15] 朱银伟,孙永安,陈俊,等. 磁共振帕金森指数对进行性核上性麻痹的诊治提示[J]. 中国神经精神疾病杂志, 2012, 38(9):547-550.
[16] Wang G, Wang J, Zhan J, et al. Quantitative assessment of cerebral gray matter density change in progressive supranuclear palsy using voxel based morphometry analysis and cerebral MR T1-weighted FLAIR imaging [J]. J Neurol Sci, 2015, 359(1-2): 367-372.
[17] Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy [J]. Brain, 2007, 130(Pt 6): 1552-1565.
[18] Hall DA, Forjaz MJ, Golbe LI, et al. Scales to assess clinical features of progressive supranuclear palsy: MDS task force report [J]. Mov Disord Clin Pract, 2015, 2(2): 127-134.
[19] Ghosh BC, Carpenter RH, Rowe JB. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy [J]. PLoS One, 2013, 8(9): e74486.
[20] Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis [J]. Alzheimers Dement, 2010, 6(1): 70-74.
[21] Stamelou M, de Silva R, Arias-Carrión O, et al. Rational therapeutic approaches to progressive supranuclear palsy [J]. Brain, 2010, 133(Pt 6): 1578-1590.
[22] Lamb R, Rohrer JD, Lees AJ, et al. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options [J]. Curr Treat Options Neurol, 2016, 18(9): 42.
[23] Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy [J]. N Engl J Med, 1999, 341(7): 543-544.
[24] Chang AY, Weirich E. Trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy [J]. Case Rep Med, 2014, 2014: 107064.
[25] Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy [J]. Neurology, 2001, 57(3): 467-473.
[26] Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial [J]. Lancet Neurol, 2014, 13(7): 676-685.
[27] Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy [J]. Mov Disord, 2014, 29(4): 470-478.
[28] Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial [J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3(5): e266.
[29] Nuebling G, Hensler M, Paul S, et al. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy [J]. J Neurol, 2016, 263(8): 1565-1574.
[30] Choi SW, Park KB, Woo SK, et al. Treatment of progressive supranuclear palsy with autologous adipose tissue-derived mesenchymal stem cells: a case report [J]. J Med Case Rep, 2014, 8: 87.
[31] Giordano R, Canesi M, Isalberti M, et al. Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study [J]. J Transl Med, 2014, 12: 14.
[32] Servello D, Zekaj E, Saleh C, et al. Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: report of three cases [J]. Surg Neurol Int, 2014, 5(Suppl 8): S416-S420.
[33] Izzo KL, DiLorenzo P, Roth A. Rehabilitation in progressive supranuclear palsy: case report [J]. Arch Phys Med Rehabil, 1986, 67(7): 473-476.
[34] Zampieri C, Di FRP. Balance and eye movement training to improve gait in people with progressive supranuclear palsy: quasi-randomized clinical trial [J]. Phys Ther, 2008, 88(12): 1460-1473.
[35] Sale P, Castiglioni D, De Pandis MF, et al. The Lee Silverman Voice Treatment (LSVT ® ) speech therapy in progressive supranuclear palsy [J]. Eur J Phys Rehabil Med, 2015, 51(5): 569-574.
[36] Sale P, Stocchi F, Galafate D, et al. Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report [J]. Front Hum Neurosci, 2014, 8: 207.
[37] Suteerawattananon M, MacNeill B, Protas EJ. Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy [J]. Phys Ther, 2002, 82(5): 485-495.
[38] Steffen TM, Boeve BF, Petersen CM, et al. Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up [J]. Phys Ther, 2014, 94(2): 289-296.
[39] Seamon B, DeFranco M, Thigpen M. Use of the Xbox Kinect virtual gaming system to improve gait, postural control and cognitive awareness in an individual with progressive supranuclear palsy [J]. Disabil Rehabil, 2017, 39(7): 721-726.
[40] Hanson WR, Metter EJ. DAF as instrumental treatment for dysarthria in progressive supranuclear palsy: a case report [J]. J Speech Hear Disord, 1980, 45(2): 268-276.
[41] Boulogne S, Le CF, Bation R, et al. Repetitive transcranial magnetic stimulation can alleviate treatment-resistant depression in patients with progressive supranuclear palsy [J]. Parkinsonism Relat Disord, 2015, 21(9): 1113-1114.
[42] Dunlop SR, Kent VP, Lashley M, et al. The cure PSP care guide: a telephonic nursing intervention for individuals and families living with progressive supranuclear palsy [J]. J Neurosci Nurs, 2016, 48(2): 105-106.
[43] Golbe LI, Davis PH, Schoenberg BS, et al. Prevalence and natural history of progressive supranuclear palsy [J]. Neurology, 1988, 38(7): 1031-1034.
[44] Oropesa-Ruiz JM, Huertas-Fernández I, Jesús S, et al. Low serum uric acid levels in progressive supranuclear palsy [J]. Mov Disord, 2016, 31(3): 402-405.
[45] Tomita S, Oeda T, Umemura A, et al. Impact of aspiration pneumonia on the clinical course of progressive supranuclear palsy: a retrospective cohort study [J]. PLoS One, 2015, 10(8): e0135823.
[46] Nozaki I, Kato-Motozaki Y, Ikeda T, et al. Aspiration pneumonia and bronchopneumonia in progressive supranuclear palsy treated with Qing Fei Tang: two case reports [J]. J Med Case Rep, 2015, 9: 67.
Options
Outlines

/

〈 〉